---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-453913"
form_type: "8-K"
ticker: "LNTH"
cik: "0001521036"
company_name: "Lantheus Holdings, Inc."
filed_at: "2026-11-09T22:40:18+00:00"
generated_at: "2026-11-10T11:05:06.393601+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Lantheus to sell CDMO business and Springfield, NJ plant to PharmaLogic; signs Lu-177 dotatate supply deal

## Summary
- Definitive agreement dated Nov. 8, 2026 to sell Lantheus's contract development and manufacturing organization (CDMO) business and its Springfield, New Jersey facility to PharmaLogic Holdings Corp.
- No purchase price or other financial terms disclosed; closing is subject to customary closing conditions and regulatory approvals.
- Under a long-term supply agreement, PharmaLogic's therapeutic CDMO franchise Agilera will manufacture lutetium Lu 177 dotatate for Lantheus.
- Lantheus will provide certain transition services to PharmaLogic immediately after closing.
- Company flags risks that conditions may not be satisfied and that anticipated benefits may take longer to realize or involve unexpected costs.

## SEC filing metadata
- accession: 0001193125-26-453913
- form_type: 8-K
- ticker: LNTH
- cik: 0001521036
- company_name: Lantheus Holdings, Inc.
- filed_at: 2026-11-09T22:40:18+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1521036/000119312526453913/0001193125-26-453913-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1521036/000119312526453913/d166239d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-453913
- JSON: https://secwatch.observer/filing/0001193125-26-453913.json
- Plain text: https://secwatch.observer/filing/0001193125-26-453913.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.